The UK and US have agreed to a important trade agreement that will preserve zero levies on British drug shipments entering the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has pledged to raise funding on drugs through the NHS. This move secures that duties on these crucial goods will stay at zero for a timeframe of the next three years.
This deal is in response to recent warnings to dramatically increase tariffs on patented pharmaceutical imports, with potential rates discussed reaching 100%.
"This arrangement between the Britain bolsters the worldwide climate for innovative medicines and introduces long-overdue equity to transatlantic pharmaceutical trade," a release declared.
Commercial Impact
Drugs represent one of the UK's most significant goods shipped to the US, which is clearly the largest buyer for major UK drugmakers.
Statistics indicate that in the one-year period to the end of last September, the UK exported drugs totaling billions to the US. This amount accounted for 17.4% of total UK exports in that span.
"This guarantee secures work, increases capital expenditure and paves the way for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary remarked.
Detailed British Pledges
The deal involves several key pledges from the British government:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it deems new treatments to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a aim to raise total NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Refund Ceiling: The sum drug companies must pay back to the NHS to control costs will be limited at 15%. Last year, refunds were more than 20%.
Industry Background
The pact comes amid a ongoing dispute between the pharmaceutical industry and the ministers over spending levels and approval rates.
This friction were heightened by claims that American customers were charged a premium for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been delayed or scrapped, while substantial investments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS had to spend more on drugs, noting that its expenditure on drugs had shrunk as a proportion of its resources over the previous ten-year period.
